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gTrileaflet Polytetrafluoroethylene Valved
Conduit for Pulmonary Reconstruction
Makoto Ando, MD, and Yukihiro Takahashi, MDlExtracardiac conduits, used for pulmonary reconstructionin congenital heart surgery, inevitably fail in the long
erm. This is even true with homografts, which have been the
old standard, and calcific fibrosis has been noted particu-
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doi:10.1053/j.optechstcvs.2011.02.002arly in young children.1-3 Furthermore, homografts are not
always available and xenografts or other synthetic conduits have
been used as alternatives.4 Polytetrafluoroethylene (PTFE) is
chemically inert and has low friction; these properties prevent
tissue ingrowth, and future degeneration or calcification. PTFE,
therefore, has been used as a pulmonary valve substitute in
many centers.5 In our institute we have used a trileaflet valve
made of PTFE, which is incorporated into a Dacron conduit, for
pulmonary reconstruction, since 1997. The details of the con-
struction process and results are presented.
Trileaflet PTFE valved conduit 169Operative Technique
Figure 1 A Dacron conduit (Hemashield; Boston Scientific Corporate, Natick, MA) of an appropriate size is first chosen. A
0.1-mm PTFE membrane (Gore-Tex; W. L. Gore & Associates, Inc., Newark, DE) is cut in a rectangular shape (A). As is
shown, 6 equal-sized rectangular grids are drawn on both sides of the sheet using amarking pen, leaving a 1-mmmargin on
both sides and a 2-mmmargin at the top. Thewidth of each cellmeasures (diameter of theDacron conduit) 1.05mm. The
height of each cell measures (diameter of the Dacron conduit) 0.84 mm. The 3 cells on the bottom row become the valve
leaflets, whereas the cells on the upper row become the sinuses facing these leaflets. The PTFE membrane is then folded so
that the cells in the upper and bottom rows face each other (B).
170 M. Ando and Y. TakahashiFigure 2 (A) Three isolated pockets are then created. This is achieved by placing continuous sutures on the 2 lines of
separation previously drawn. The needle is placed from the outside to inside first and then from the inside to outside,
as is shown in the side view (B). This alternating stitching is repeated, so that the suture line becomes completely
straight. Finally, the knot is tied outside the sheet. 5-0 polypropylene sutures are typically used throughout this
construction process.
Trileaflet PTFE valved conduit 171Figure 3 The PTFE sheet is folded in half and both ends are sutured together. This suture line is placed on the margin
lines drawn on both ends of the sheet. The suturing technique applied on this line is identical to that shown in Figure
2B. The sheet is then unfolded, forming a cylinder with 3 pockets on the inside. Note that all tying knots are placed
outside the sheet, to avoid creating clot formation points.
172 M. Ando and Y. TakahashiFigure 4 This valve is now pushed inside the Dacron conduit. The valve is positioned near the distal end of the conduit.
The distance between the top (outflow) end of the PTFE sheet and the distal end of the conduit is approximately 2 cm.
If pushed inside too far, the precise suturing of the bottom end of the valve becomes difficult (see Fig. 5 legend). The
position of the valve, however, can differ according to the anatomy of the heart (the appropriate height of the valve to
be placed relative to the pulmonary artery).
Trileaflet PTFE valved conduit 173Figure 5 The PTFE sheet is fixed inside the Dacron conduit by suturing the top and bottom ends of the PTFE valve. This
suture can be placed from the outside of the conduit in a continuous fashion. However, this is more precisely done by
placing the needle alternately from inside and outside (Fig. 2B). Because these needle placements are done by handling
the holder through the distal end of the conduit, it is more convenient to place the valve distally.
174 M. Ando and Y. TakahashiFigure 6 After fixing the valve to the con-
duit, simple commissural sutures are
placed approximately 1 mm from the com-
missure. This distance can differ depend-
ing on the size of the conduit. The aim of
these sutures is to further improve valve
coaptation. PTFE, polytetrafluoroethylene.
Trileaflet PTFE valved conduit 175Figure 7 Finally, a fixing suture is placed from the midpoint of the sinus through the conduit to prevent free-floating of
the valve. This tying knot is placed outside the conduit (outer PTFE suture in the figures). PTFE, polytetrafluoroeth-
ylene.
176 M. Ando and Y. TakahashiFigure 8 A standard first-time or redo median sternotomy is performed. Cardiopulmonary bypass is established with
ascending aortic and bicaval cannulations. If present, the ventricular septal defect is first closed. After creation of the
openings in the pulmonary artery and the right ventricle (left ventricle in patients with corrected transposition of the
great arteries), the conduit is cut to the appropriate length. The distal end of the conduit is trimmed off 0.5 to 1 cm from
the distal margin of the PTFE valve. The distal anastomosis of the conduit with the pulmonary artery is first performed
using a running suture.
Trileaflet PTFE valved conduit 177Figure 9 The proximal end is then trimmed to an appropriate shape, and the proximal anastomosis with the ventricle
is performed using a running suture. If the right ventricular muscle seems to be weak, a strip of autologous pericardium
is placed on the suture line. This strip, by being included into each stitch, reinforces the suture line and avoids cutting
the muscle.
t
p
p
g
p
p
d
1
(
l
178 M. Ando and Y. TakahashiResults
One hundred eighty-nine patients underwent pulmonary re-
construction using this PTFE conduit. There were 80 female
patients. Mean age and bodyweight at operationwere 12.4
12.5 (0.02-62.5) years and 29.1 20.6 (2.6-101) kg, respec-
ively. Conduits were placed from the left ventricle to the
ulmonary artery in 14 patients (the conventional Rastelli
rocedure for patients with corrected transposition of the
reat arteries). There were 80 (42.3%) reoperations following
revious Rastelli procedures, Ross procedures, or repairs em-
loying right ventricular outflow reconstruction. The con-
uit size was 12 mm (10 patients), 14 mm (15), 16 mm (28),
8 mm (26), 20 mm (18), 22 mm (29), 24 mm (33), 26 mm
29), and 28 mm (1).
The longest follow-up period was 3.3 (mean 1.5 1.8)
years for small-sized conduits (12 and 14 mm), 7.3 (3.1 
2.1) years for middle-sized conduits (16 and 18 mm), and
12.1 (4.7  3.3) years for large-sized conduits (20 mm or
arger). The Z-score for each group was1.5 1.8,2.0
1.0, and 1.0  0.8, respectively. Conduit replacements
were performed in 9 patients. Five conduits were replaced,
even though they were still functional, concomitantly with
various procedures for other abnormalities (eg, aortic valve
replacement for regurgitation). In the remainder, conduit
insufficiency was the main reason for replacement, due to
conduit infection in 3 and somatic overgrowth in 1. Esti-
mated freedom from conduit replacement was 86.4  9.4%
at 3 years for conduit sizes 12 and 14 mm; 94.7 5.1% at 7
years for sizes 16 and 18 mm; and 83.9 16.1% at 12 yearsfor sizes 20 mm or larger. The mean estimated pressure gra-
dient across the conduit was 10.7  6.4 mmHg (12 and 14
mm), 11.2  6.0 mmHg (16 and 18 mm), and 10.7  6.5
mmHg (20 mm or larger) immediately after operation. The
degree of pulmonary insufficiency was equal to or less than
mild in all patients at the time of last follow-up for sizes 12 to
18 mm, and in 72.0% at 10 years for sizes 20 mm or larger.
PTFE valved conduits had good functional durability. The
valve retained its motion in all patients. Currently it can be
constructed from size 12 mm and this small-sized conduit
seems to function well up to 3 years. The PTFE conduit, in
our own experience, is a reliable alternative to homograft or
other xenograft materials for pulmonary reconstruction.
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